RLYB•benzinga•
Rallybio to Discontinue Development Of RLYB212 In Prevention Of FNAIT, Says RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga